AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-588-1960
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.41 million
Profitability
Miscellaneous
Employees17
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.05. The biopharmaceutical company had revenue of $0.70 million for the quarter, compared to analysts' expectations of $1.78 million. AVEO Pharmaceuticals had a negative net margin of 46.69% and a negative return on equity of 50.69%. View AVEO Pharmaceuticals' Earnings History.
When is AVEO Pharmaceuticals' next earnings date?
What price target have analysts set for AVEO?
6 equities research analysts have issued 12-month price objectives for AVEO Pharmaceuticals' stock. Their forecasts range from $1.00 to $4.00. On average, they expect AVEO Pharmaceuticals' stock price to reach $2.55 in the next twelve months. This suggests a possible upside of 157.2% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.
What is the consensus analysts' recommendation for AVEO Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AVEO Pharmaceuticals.
What are Wall Street analysts saying about AVEO Pharmaceuticals stock?
Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We raise our rating on AVEO to and increase our 12-month price target to $1.75 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030, assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $393M for the products and add in pro forma net cash and cash equivalents of $65.2M to arrive at a 12-month price target of $1.75 per share. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (9/11/2019)
- 2. According to Zacks Investment Research, "AVEO missed on both earnings and revenues in the first quarter of 2019. The company got a huge boost from the approval for Fotivda in Europe regarding the first-line treatment of advanced renal cell carcinoma (RCC).However, AVEO faced a major setback when it had to delay its submission of a new drug application (NDA) for Fotivda in the United States. The company intended to submit the NDA in the first half of 2019 but now interim data will be available during the fourth quarter of 2019, subject to mature OS results. Although, the target market is lucrative, dependence on partners for pipeline development and funds accumulation is a concern. Failure to receive regulatory approvals or the termination of a deal would hamper AVEO’s future prospects. AVEO receives royalties from Fotivda sales in certain European countries. This is a key revenue driver. Shares of the company have underperformed the industry so far this year." (5/15/2019)
Has AVEO Pharmaceuticals been receiving favorable news coverage?
News stories about AVEO stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for AVEO Pharmaceuticals.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Akero Therapeutics (AKRO), Synthorx (THOR), Organogenesis (ORGO), Myovant Sciences (MYOV), Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), DiaMedica Therapeutics (DMCAF), Flexion Therapeutics (FLXN), Achillion Pharmaceuticals (ACHN), Milestone Pharmaceuticals (MIST), Lannett (LCI), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI) and Basilea Pharmaceutica (BPMUF).
What other stocks do shareholders of AVEO Pharmaceuticals own?
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
- Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 42)
- Dr. Michael N. Needle, Chief Medical Officer (Age 59)
- Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
- Dr. Emile Farhan Ph.D., VP of Technical Operations
Who are AVEO Pharmaceuticals' major shareholders?
AVEO Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (15.70%), Vanguard Group Inc. (4.77%), BlackRock Inc. (1.24%), Northern Trust Corp (0.69%), Paloma Partners Management Co (0.30%) and Morgan Stanley (0.25%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.
Which institutional investors are selling AVEO Pharmaceuticals stock?
AVEO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., GSA Capital Partners LLP, Bank of New York Mellon Corp, D. E. Shaw & Co. Inc., Wells Fargo & Company MN and Northern Trust Corp. View Insider Buying and Selling for AVEO Pharmaceuticals.
Which institutional investors are buying AVEO Pharmaceuticals stock?
AVEO stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Vanguard Group Inc., Paloma Partners Management Co, OZ Management LP, Morgan Stanley, Jane Street Group LLC, Anson Funds Management LP and Cetera Advisor Networks LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.
How do I buy shares of AVEO Pharmaceuticals?
Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO stock can currently be purchased for approximately $0.9914.
How big of a company is AVEO Pharmaceuticals?
AVEO Pharmaceuticals has a market capitalization of $159.36 million and generates $5.41 million in revenue each year. The biopharmaceutical company earns $-5,330,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe.View Additional Information About AVEO Pharmaceuticals.
What is AVEO Pharmaceuticals' official website?
How can I contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]
MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
